161 related articles for article (PubMed ID: 35213749)
1. Metformin and the risk of neurodegenerative diseases in patients with diabetes: A meta-analysis of population-based cohort studies.
Zhang Y; Zhang Y; Shi X; Han J; Lin B; Peng W; Mei Z; Lin Y
Diabet Med; 2022 Jun; 39(6):e14821. PubMed ID: 35213749
[TBL] [Abstract][Full Text] [Related]
2. Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis.
Ping F; Jiang N; Li Y
BMJ Open Diabetes Res Care; 2020 Jul; 8(1):. PubMed ID: 32719079
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of metformin alone or as an add-on therapy to insulin in pregnancy with GDM or T2DM: A systematic review and meta-analysis of 21 randomized controlled trials.
He K; Guo Q; Ge J; Li J; Li C; Jing Z
J Clin Pharm Ther; 2022 Feb; 47(2):168-177. PubMed ID: 34363237
[TBL] [Abstract][Full Text] [Related]
4. Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis.
Mekuria AN; Ayele Y; Tola A; Mishore KM
J Diabetes Res; 2019; 2019():7676909. PubMed ID: 31828167
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
6. Metformin use and prostate cancer risk: A meta-analysis of cohort studies.
Feng Z; Zhou X; Liu N; Wang J; Chen X; Xu X
Medicine (Baltimore); 2019 Mar; 98(12):e14955. PubMed ID: 30896668
[TBL] [Abstract][Full Text] [Related]
7. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Wang Z; Lai ST; Xie L; Zhao JD; Ma NY; Zhu J; Ren ZG; Jiang GL
Diabetes Res Clin Pract; 2014 Oct; 106(1):19-26. PubMed ID: 24837144
[TBL] [Abstract][Full Text] [Related]
8. Metformin Use and Risk of All-Cause Mortality and Cardiovascular Events in Patients With Chronic Kidney Disease-A Systematic Review and Meta-Analysis.
Hu Y; Lei M; Ke G; Huang X; Peng X; Zhong L; Fu P
Front Endocrinol (Lausanne); 2020; 11():559446. PubMed ID: 33117278
[TBL] [Abstract][Full Text] [Related]
9. Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus.
Shi Q; Liu S; Fonseca VA; Thethi TK; Shi L
BMJ Open; 2019 Jul; 9(7):e024954. PubMed ID: 31366635
[TBL] [Abstract][Full Text] [Related]
10. Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies.
Liang H; Ding X; Li L; Wang T; Kan Q; Wang L; Sun T
Crit Care; 2019 Feb; 23(1):50. PubMed ID: 30777119
[TBL] [Abstract][Full Text] [Related]
11. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes.
Griffin SJ; Leaver JK; Irving GJ
Diabetologia; 2017 Sep; 60(9):1620-1629. PubMed ID: 28770324
[TBL] [Abstract][Full Text] [Related]
12. Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis.
Meng F; Song L; Wang W
J Diabetes Res; 2017; 2017():5063239. PubMed ID: 28271076
[No Abstract] [Full Text] [Related]
13. Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis.
Tian RH; Zhang YG; Wu Z; Liu X; Yang JW; Ji HL
Clin Transl Oncol; 2016 Jun; 18(6):641-9. PubMed ID: 26459254
[TBL] [Abstract][Full Text] [Related]
14. Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis.
Yao L; Liu M; Huang Y; Wu K; Huang X; Zhao Y; He W; Zhang R
Dis Markers; 2019; 2019():6230162. PubMed ID: 30881522
[TBL] [Abstract][Full Text] [Related]
15. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus.
Kuan YC; Huang KW; Lin CL; Hu CJ; Kao CH
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):77-83. PubMed ID: 28583443
[TBL] [Abstract][Full Text] [Related]
16. The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis.
Hu J; Fan HD; Gong JP; Mao QS
BMC Gastroenterol; 2023 Feb; 23(1):50. PubMed ID: 36829129
[TBL] [Abstract][Full Text] [Related]
17. For colorectal cancer patients with type II diabetes, could metformin improve the survival rate? A meta-analysis.
Cheng Y; Chen Y; Zhou C; Shen L; Tu F; Xu J; Liu C
Clin Res Hepatol Gastroenterol; 2020 Feb; 44(1):73-81. PubMed ID: 31300371
[TBL] [Abstract][Full Text] [Related]
18. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
19. Association of metformin use with fracture risk in type 2 diabetes: A systematic review and meta-analysis of observational studies.
Wang Y; Yu L; Ye Z; Lin R; Sun AR; Liu L; Wei J; Deng F; Zhong X; Cui L; Li L; Liu Y
Front Endocrinol (Lausanne); 2022; 13():1038603. PubMed ID: 36714564
[TBL] [Abstract][Full Text] [Related]
20. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis.
Noto H; Goto A; Tsujimoto T; Noda M
PLoS One; 2012; 7(3):e33411. PubMed ID: 22448244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
